[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"normal-tension-glaucoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:normal-tension-glaucoma":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,79,103,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100568571","transcorneal-electrical-stimulation-for-the-treatment-of-visual-field-defects-in-patients-with-open-angle-glaucoma-100568571",false,"NCT06682962","Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle Glaucoma","Transcorneal Electrical Stimulation for the Treatment of Visual Field Defects in Patients With Open-Angle Glaucoma - a Monocentric, Randomized, Double-Masked, Sham-Controlled Pilot Study","TES-GPS","Inclusion Criteria:\n\n1. Willingness to participate in the study, the subjects signed and dated informed consent must be submitted before the start of the screening\n2. Age ≥ 40 years\n3. Primary open-angle glaucoma, pseudoexfoliation glaucoma, pigment dispersion glaucoma or normal tension glaucoma (according to the EGS criteria) in the study eye\n4. Current progression in perimetry of at least 1.5 dB per year in the study eye and mean defect (MD) in the study eye between ≥ 6 and ≤ 12 dB (Octopus visual field) or ≤ -6 and ≥ -12 dB (Humphrey visual field) in the screening examination as the mean value of the two visual field examinations carried out as part of the screening (permitted deviation maximum 2 dB)\n5. Visual acuity ≥ 0.2 decimal in the study eye (corresponds to a visual acuity of 0.7 logMAR)\n6. The patient must master home stimulation after extensive training.\n7. Ability of subject to understand the scope, significance and individual consequences of participation in the study\n8. Ability of subject to give consent\n9. If both eyes meet the inclusion\u002Fexclusion criteria, the eye with the higher MD is selected as the study eye. If the MD is the same in both eyes, the eye with the worse visual acuity will be selected as the study eye. If there is no difference between the eyes, the right eye will be selected as the study eye\n10. Negative serum or urine pregnancy test at screening in women of childbearing potential. Participants are considered to be of nonchildbearing potential if they are postmenopausal and have not menstruated for at least 12 months prior to screening or if they are surgically sterile\n11. Women of childbearing potential must agree to be abstinent or to use highly effective methods of contraception that result in a failure rate of less than 1% per year. This applies consistently throughout the duration of the treatment once you have given your consent to participate in the study.\n\nExclusion Criteria:\n\n1. Neovascularisations of any origin in the study eye\n2. Condition after arterial or venous occlusions in the study eye\n3. Condition after intraocular surgery in the last 3 months before the screening examination in the study eye\n4. Acute (intra)ocular inflammation in any eye\n5. Non-proliferative or proliferative diabetic retinopathy in the study eye\n6. Condition after retinal detachment in the study eye\n7. Dry age-related macular degeneration affecting the visual field in the study eye\n8. Exsudative age-related macular degeneration in the study eye\n9. Macular edema of any origin in the study eye\n10. Other relevant retinal diseases in the study eye\n11. Any form of corneal degeneration that limits vision in the study eye\n12. Any disease other than glaucoma affecting the central 30° visual field in the study eye\n13. No cataract surgery or other eye surgery may be planned for the patient in the study eye during the duration of the study (except laser trabeculoplasty)\n14. Patients with active implants\n15. General illnesses that are difficult to control\u002Fadjust and which, in the opinion of the investigator, could jeopardize regular study routines\n16. Poor general condition according to the investigators assessment\n17. Mental illness or dementia, that, in the opinion of the investigator, reduces the understanding of the study procedures and use of the Okustim 2 System\n18. Simultaneous participation in another interventional study or past interventions whose effect may still be ongoing (30 days)\n19. Breastfeeding women\n20. Patients unable to consent\n21. Previous enrolment in the TES-GPS study\n22. Contraindications to the use of OkuStim 2 such as allergies\u002Fhypersensitivity to silver","ALL","40 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","Glaucoma is a progressive optic neuropathy with retinal ganglion cell loss which leads to visual field loss. Open-angle glaucoma is the most common form of glaucoma.\n\nThe aim of this pilot study is to evaluate the safety and effectiveness of the treatment of visual field defects using transcorneal electrical stimulation (TES) with the OkuStim 2 System in patients with primary open-angle glaucoma, pseudoexfoliation glaucoma, pigment dispersion glaucoma or normal tension glaucoma.",[27,28,29,30,31],"Glaucoma","Primary Open Angle Glaucoma","Pseudoexfoliation Glaucoma","Pigment Dispersion Glaucoma","Normal Tension Glaucoma",[33,34,35,36,37,27,38],"TES","TcES","POAG","OkuStim","Okuvision","Electrical Stimulation","RECRUITING","2026-03-10",{"date":42,"type":43},"2026-03-12","ACTUAL",{"date":45,"type":43},"2025-04-02",{"date":47,"type":21},"2028-06",{"name":49,"class":50},"Okuvision GmbH","INDUSTRY",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100517929","obstructive-sleep-apnea-as-a-risk-factor-for-normal-tension-glaucoma-and-a-crucial-step-in-preventing-blindness-100517929","NCT06023927","Obstructive Sleep Apnea as a Risk Factor for Normal Tension Glaucoma and a Crucial Step in Preventing Blindness","Inclusion Criteria:\n\n* Newly diagnosed subjects with OSA that will undergo CPAP treatment.\n* At least 21 years of age\n* Best corrected vision of 20\u002F40 or better, spherical Rx \\\u003C ± 6.0 Diopter, and cylinder \\\u003C-3.0D\n* Ability to follow instructions, and intent to complete all study visits\n\nExclusion Criteria:\n\n* High Rx \\>± 6.0D and cylinder \\> -3.0D\n* Narrow angle glaucoma\n* History of any of the following: severe eye trauma, ocular inflammation, previous intraocular surgery except for uncomplicated cataract extraction with posterior chamber intraocular lens implantation.\n* Any medical or ocular condition which is not appropriate for participation in the trial (Diabetic retinopathy, and other retinal changes preventing reliable optic disc evaluation) Hypersensitivity to any component of altafluor benox","21 Years",{"count":60,"type":21},100,"OBSERVATIONAL","The purpose of this research study is to learn more about the relationship between Obstructive Sleep Apnea (OSA) and Normal Tension Glaucoma (NTG). OSA is a nighttime disorder of the upper airway that causes an intermittent lack of oxygen while sleeping. NTG is a type of glaucoma that occurs despite the normal intraocular pressure levels, making its detection more difficult. Left untreated, irreversible optic nerve damage and extensive vision loss can result. Previous research has shown some evidence between OSA and the development of NTG. The investigators are researching whether undergoing treatment for OSA would help to improve the vascular health to the retina, and in effect, improve the early signs of visual dysfunction seen with diagnostic testing.",[31,64],"Obstructive Sleep Apnea",[66],"Glaucoma, obstructive sleep apnea Syndrome","NOT_YET_RECRUITING","2025-06-05",{"date":70,"type":43},"2025-06-10",{"date":72,"type":21},"2025-09-02",{"date":74,"type":21},"2028-09-01",{"name":76,"class":77},"Northwell Health","OTHER",2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":51},"100352543","investigation-of-neurovascular-coupling-in-glaucoma-patients-and-healthy-subjects-100352543","NCT03870230","Investigation of Neurovascular Coupling in Glaucoma Patients and Healthy Subjects","Inclusion criteria\n\nPatients with primary open angle glaucoma\n\n* Diagnosis of manifest primary open angle glaucoma defined as pathological optic disc appearance\n* Glaucoma hemifield test outside normal limits\n* Untreated IOP ≥ 21 mmHg on at least three measurements in the medical history\n* Mean deviation in the visual field test is less than or equal 10dB (for one group) OR more than 10dB (for the other group)\n\nPatients with normal tension glaucoma\n\n* Diagnosis of manifest normal tension glaucoma defined as pathological optic disc appearance\n* Glaucoma hemifield test outside normal limits\n* No evidence of untreated IOP \\> 20 mmHg in the medical history\n* Mean deviation in the visual field is less than or equal 10dB (for one group) OR more than 10dB (for the other group)\n\nPatients with ocular hypertension\n\n* Normal ophthalmic findings except presence of ocular hypertension defined as untreated IOP ≥ 21 mmHg on at least three measurements in the medical history\n* No signs of glaucomatous damage in the optic disc\n* or the glaucoma hemifield test\n\nHealthy control subjects\n\n* Normal ophthalmic findings\n* IOP \\\u003C 20 mmHg on least three measurements\n* No evidence of increased IOP in the medical history\n* No signs of glaucomatous damage in the optic disc\n* or the glaucoma hemifield test\n\nExclusion criteria\n\n* History of a severe medical condition as judged by the clinical investigator\n* Abuse of alcoholic beverages\n* Smoker\n* Participation in a clinical trial in the 3 weeks preceding the study\n* Exfoliation glaucoma, pigmentary glaucoma, history of acute angle closure\n* Intraocular surgery within the last 6 months\n* Ocular inflammation or infection within the last 3 months\n* History of epilepsia\n* Diabetes mellitus\n* Untreated hypertension with systolic blood pressure \\> 160 mmHg, diastolic blood pressure \\> 95 mmHg\n* Pregnancy\n* Planned pregnancy or lactating",true,"18 Years",{"count":88,"type":21},120,[24],"Glaucoma is characterized by a progressive loss of retinal ganglion cells (RGCs) leading to optic nerve head (ONH) damage and associated visual field defects. The main risk factor for glaucoma is elevated intraocular pressure (IOP). Reducing IOP slows down the progression of the disease as several large multicenter trials have shown. Some patients, however, still progress despite adequately controlled IOP. As such, there is considerable interest in approaches that rescue RGCs independent of IOP, a strategy called neuroprotection. Although this field was actively discovered in the last 20 years in the brain and the eye, no non-IOP related treatment is clinically available to date. Various approaches are currently studied in some detail. One interesting strategy focuses on the neurovascular unit.\n\nThe blood flow of the human retina is controlled by complex mechanisms that include myogenic, metabolic and hormonal factors. The high consumption of oxygen in the human retina is crucial for normal functioning of the organ. As in the brain, blood flow in the retina is also controlled by neurovascular coupling. This means that the retina increases its blood flow to regions in which neurons are activated. This is done in an effort to provide more oxygen and glucose to the active neurons. In the recent years evidence has accumulated that astrocytes play a key role in mediating this vasodilator signal.\n\nIn the brain, abnormalities in neurovascular coupling have been observed in diseases like stroke, hypertension, spinal-cord injury and Alzheimer's disease. This break-down of neurovascular coupling is considered to play a key role in neuronal death in these diseases. In the retina, abnormalities in neurovascular coupling have been observed in diseases as diabetes and glaucoma.\n\nMost of the data obtained in the human retina stem from a system that measures retinal vasodilatation during stimulation with flickering light. The investigators have previously shown that flicker stimulation of the retina is, however, also associated with a pronounced increase in retinal blood velocities. In this study the investigators employed laser Doppler velocimetry (LDV) for the measurement of retinal blood velocities, but this technique is not clinically applicable because it requires excellent fixation of the subject under study. In the present study, the investigators propose to use an alternative system for neurovascular coupling that they have developed recently. In this approach, the investigators use bi-directional Fourier-domain optical coherence tomography for the assessment of retinal blood flow. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology, OCT has become a standard tool in visualizing the retina and nowadays is considered also as a standard tool in the diagnosis of retinal disease. In the recent years, conventional time domain OCT was replaced by Fourier domain OCT providing significantly improved signal quality.\n\nThis bidirectional system overcomes the limitations of previously realized techniques, which include doubtful validity and limited reproducibility. In addition, pattern ERG, multifocal ERG and oscillatory potentials will be measured to allow for concomitant assessment of neural function.\n\nThe investigators seek to measure neurovascular coupling in the human retina in patients with early primary open angle glaucoma (POAG), normal tension glaucoma, ocular hypertension and a healthy control group. In order to obtain information on neurovascular coupling, both neuronal function as well as retinal blood flow need to be measured. In the present study, the investigators will employ pattern ERG, multifocal ERG as well as oscillatory potentials to assess the function of the inner retina. Retinal blood flow through major retinal arterial and venous branch vessels will be measured before, during and after flicker stimulation with the dual-beam bidirectional Fourier Domain Doppler OCT coupled to the commercially available Dynamic Vessel Analyzer (DVA) produced by IMEDOS, Jena, Germany, which provides adequate resolution to study the retinal circulation.",[92,31,93],"Glaucoma, Open-Angle","Ocular Hypertension","2025-05-20",{"date":96,"type":43},"2025-05-23",{"date":98,"type":43},"2017-12-01",{"date":100,"type":21},"2026-03",{"name":102,"class":77},"Medical University of Vienna",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":51},"100467838","deep-sclerectomy-versus-trabeculectomy-in-normal-tension-glaucoma-100467838","NCT05371977","Deep Sclerectomy Versus Trabeculectomy in Normal Tension Glaucoma","DSTRENTG","Inclusion Criteria:\n\n* Signed Informed Consent\n* Normal Tension Glaucoma with typical nerve fiber layer defects in red-free photographs and\u002For optical coherence tomography (OCT) and possible equivalent visual field defects, IOP never more than 21 mmHg, and open anterior chamber angle\n* Glaucoma unstable with current medication assessed by a glaucoma specialist\n\nExclusion Criteria:\n\n* Secondary Glaucoma e.g. due to previous injury or uveitis\n* Exfoliation syndrome\n* Pigment dispersion syndrome\n* Previous transscleral or endoscopic cyclophotocoagulation\n* Previous other glaucoma surgery\n* Previous retinal detachment\n* Previous intraocular surgery like vitrectomy and other retinal surgery\n* Wet age-related macular degeneration\n* Diabetic retonopathy\n* Previous corneal transplant or previous refractive surgery\n* Fuchs' dystrophy and other abnormalities compromising corneal clarity like scars\n* The patient does not want to participate in the study\n* The patient does not speak Finnish, Swedish or English\n* Dementia\n* Only eye with vision worse than 20\u002F200 or loss of central visual field","55 Years","100 Years",{"count":113,"type":21},80,[24],"The purpose of this study is to assess whether deep sclerectomy is as effective in lowering intraocular pressure (IOP) as trabeculectomy in patients with normal tension glaucoma.",[31],"2024-03-13",{"date":119,"type":43},"2024-03-15",{"date":121,"type":43},"2022-05-31",{"date":123,"type":21},"2029-05",{"name":125,"class":77},"Helsinki University Central Hospital",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":17,"minAge":110,"maxAge":111,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":51},"100412513","endoscopic-cyclophotocoagulation-in-normal-tension-glaucoma-100412513","NCT04651530","Endoscopic Cyclophotocoagulation in Normal Tension Glaucoma","ECPNTG","Inclusion Criteria:\n\n* Signed Informed Consent\n* Normal Tension Glaucoma with typical nerve fiber layer defects in red-free photographs and\u002For optical coherence tomography (OCT) and possible equivalent visual field defects, IOP never more than 21 mmHg, and open anterior chamber angle\n* Glaucoma stable with current medication assessed by a glaucoma specialist\n* Clinically significant cataract\n\nExclusion Criteria:\n\n* Secondary Glaucoma e.g. due to previous injury or uveitis\n* Exfoliation syndrome\n* Pigment dispersion syndrome\n* Previous transscleral or endoscopic cyclophotocoagulation\n* Previous other glaucoma surgery\n* Cataract due to eye injury or congenital cataract\n* Zonular weakness due to Marfan syndrome or other\n* Previous retinal detachment\n* Previous intraocular surgery like vitrectomy and other retinal surgery\n* Wet age-related macular degeneration\n* Diabetic retonopathy\n* Previous corneal transplant or previous refractive surgery\n* Fuchs' dystrophy and other abnormalities compromising corneal clarity like scars\n* The patient does not want to participate in the study\n* The glaucoma progresses on current IOP\n* The patient does not speak Finnish, Swedish or English\n* Dementia\n* Only eye with vision worse than 20\u002F200 or loss of central visual field",{"count":60,"type":21},[24],"The purpose of this study is to assess whether endoscopic cyclophotocoagulation added to cataract surgery lowers intraocular pressure more than cataract surgery alone in patients with normal tension glaucoma.",[31,137],"Cataract",[139,140,141],"endoscopic cyclophotocoagulation","ECP","Surgery","2020-12-18",{"date":144,"type":43},"2020-12-22",{"date":146,"type":43},"2020-12-08",{"date":148,"type":21},"2026-12-01",{"name":125,"class":77}]